ArticleFrontiers in surgery2025
Cervical Malignant Melanotic Nerve Sheath Tumor with retained PRKAR1A expression and a clinically benign course: a case report and review of the literature.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant melanotic nerve sheath tumors (MMNSTs) are rare Schwann cell-derived tumors. Previously classified as benign melanotic schwannomas, they were redefined as a potentially aggressive entity in the 2020 WHO classification of soft tissue tumors and later included in the 2021 WHO CNS classification. However, optimal therapeutic strategies remain under discussion. Case presentation: We present the case of a 46-year-old Caucasian male who underwent surgery for an intra- and extraspinal cervical mass lesion at the C4/5 level on the left side. Immunohistochemical analysis confirmed the diagnosis of MMNSTs. The patient initially presented with ataxia, left-sided weakness, and hemihypesthesia. Magnetic resonance imaging of the cervical spine revealed a left intra- and extraspinal homogeneous contrast-enhancing mass at the C4/C5 level. After the first intraspinal partial resection, the diagnosis of MMNST was established. Gross-total resection is highly recommended in nearly all cases in the literature, followed by adjuvant radiotherapy or chemotherapy in selected cases to prevent metastases, which occur in 15%-42% of cases. The patient postponed the second neurosurgical intervention and declined adjuvant radiotherapy. At 18 months after gross total resection, no recurrent tumor was detected by MRI. Conclusion: Given the limited epidemiological knowledge on MMNSTs, our study contributes to the literature by documenting a case of intra- and extraspinal, cervical MMNST without any of the previously known driver mutations or copy number changes. While the WHO 2021 classification designates these tumors as potentially malignant, our findings support existing reports that more benign courses can occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.